NICE has recommended Vanflyta (quizartinib) for routine NHS commissioning as an induction, consolidation, and maintenance ...

Japan’s Daiichi Sankyo is looking at a reduced review time for its acute myeloid leukaemia (AML) drug quizartinib in Europe, the top prospect in its new oncology pipeline. The European Medicines ...

MUNICH--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: ESPR) and Daiichi Sankyo Europe GmbH (DSE) the European headquarter organization of the Japanese pharmaceutical company Daiichi ...

Daiichi Sankyo has identified inequalities in cardiovascular disease treatment and outcomes, finding that women in Europe are less likely than men to receive lipid-lowering therapies and achieve ...

MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (CV) care ...

This summary covers significant updates in the health sector, including US Senator Bernie Sanders' push for cheaper generic ...

Two of the simplest ways to measure the success of companies that develop and commercialize drugs is to count their approvals ...

Daiichi Sankyo and AstraZeneca's ENHERTU has received ... This trial involved 866 patients across Asia, Europe, North America, Oceania and South America. With this latest BTD, ENHERTU has now ...

2 Daiichi Sankyo committed to ETNA-AF, which combines data from distinct non-interventional studies in Europe, East Asia, and Japan in a single database, to delve deeper into the global burden of CVD.

Inequalities in cardiovascular disease (CVD) care have been found, which impact clinical outcomes: Gender inequalities exist in CVD care, specifically with LDL-C goal attainment where despite ...